Gregg Nyberg is a biopharmaceutical executive with over twenty-five years of experience in process development, clinical manufacturing, technology transfer and commercialization. He is currently Chief Technology Officer at Landmark Bio, where he is responsible for translational research, process and analytical development, digital technologies and innovation, engineering, supply chain and clinical manufacturing for advanced therapies including cell and gene therapy. Prior to joining Landmark, Gregg served in multiple leadership roles at Merck, Amgen and Wyeth BioPharma/Genetics Institute. Most recently, Gregg was Head of Biologics Process Research & Development at Merck, where he was responsible for discovery interface, process development and clinical manufacturing for Merck’s biologics pipeline. Gregg received his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.